Serum inflammatory mediators as markers of human lyme disease activity.
Soloski MJ1, Crowder LA2, Lahey LJ3, Wagner CA3, Robinson WH3, Aucott JN4.
Een samenvatting van de studie is hier te lezen:
http://www.ncbi.nlm.nih.gov/pubmed/24740099
Dr. Jaller, heeft op zijn blog een stukje geschreven over dit nieuwe gepubliceerde onderzoek. Hij schrijft er o.a. over:
"A new study may help us understand why some patients get better and other don’t." ...
"This study demonstrates the exist of two distinct patient populations who have very different immunological responses to infection with Borrelia burgdorferi (Lyme) – one group has a robust response based on measurements of cytokines and markers of inflammation; the other group has a minimal immunological reaction using the same indicators. The two groups have very different clinical outcomes." ...
"One particular mediator of inflammation, IL-6 remained elevated in patients with late stage Lyme which the authors found surprising. These patients with post-treatment, symptomatic Lyme disease showed immunological evidence of persistent inflammation – or infection." ...
"This study has clearly identified a subset patient who are more likely to develop chronic Lyme disease even after IDSA recommended treatment for stage one disease. This study sheds light on why many patients are seronegative (do not make antibodies) or have weak IgM responses as we commonly see. This study lays the foundation for the development of a test which helps us predict which patients need more help early on -- those who are at higher risk for developing chronic disease."
Op de plaatsen met ... heb ik tekst weggelaten om het in te korten. Het volledige stuk van Dr. Jaller over dit gepubliceerde onderzoek is hier te lezen:
http://lymemd.blogspot.nl/2014/05/whey-do-some-patient-develop-chronic.htmlJosie
edit: titel verduidelijkt